150 related articles for article (PubMed ID: 35862378)
1. Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study.
Herman B; Wong MC; Viwattanakulvanid P
PLoS One; 2022; 17(7):e0271385. PubMed ID: 35862378
[TBL] [Abstract][Full Text] [Related]
2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
3. Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients.
Herman B; Bruni A; Zain E; Dzulhadj A; Oo AC;
PLoS One; 2022; 17(12):e0279184. PubMed ID: 36584099
[TBL] [Abstract][Full Text] [Related]
4. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
6. Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial.
Sabico S; Enani MA; Sheshah E; Aljohani NJ; Aldisi DA; Alotaibi NH; Alshingetti N; Alomar SY; Alnaami AM; Amer OE; Hussain SD; Al-Daghri NM
Nutrients; 2021 Jun; 13(7):. PubMed ID: 34202578
[TBL] [Abstract][Full Text] [Related]
7. Micronutrient supplementation in adults with HIV infection.
Visser ME; Durao S; Sinclair D; Irlam JH; Siegfried N
Cochrane Database Syst Rev; 2017 May; 5(5):CD003650. PubMed ID: 28518221
[TBL] [Abstract][Full Text] [Related]
8. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
[TBL] [Abstract][Full Text] [Related]
9. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
Çap M; Bilge Ö; Işık F; Burak C; Karagöz A; İnci Ü; Akyüz A; Aslan B; Altıntaş B; Altındağ R; Kaya İ; Adıyaman MŞ; Süleymanoğlu M; Kaya Ş; Baysal E
J Electrocardiol; 2020; 63():115-119. PubMed ID: 33181454
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients.
Yang K; Zeng J; Dai W; Chen M; Yang F
J Infect Dev Ctries; 2022 Sep; 16(9):1406-1412. PubMed ID: 36223614
[TBL] [Abstract][Full Text] [Related]
11. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.
Mutair AA; Shamou J; Alhumaid S; Layqah L; Ahmed GY; Thoyaja K; Mohaini MA; Almahmoud S; Barry M; Khan A; Dhama K; Al-Jamea LH; Woodman A; Rabaan AA
J Infect Public Health; 2022 Apr; 15(4):389-394. PubMed ID: 35299062
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
[TBL] [Abstract][Full Text] [Related]
13. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
[TBL] [Abstract][Full Text] [Related]
14. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
Marlin R; Desjardins D; Contreras V; Lingas G; Solas C; Roques P; Naninck T; Pascal Q; Behillil S; Maisonnasse P; Lemaitre J; Kahlaoui N; Delache B; Pizzorno A; Nougairede A; Ludot C; Terrier O; Dereuddre-Bosquet N; Relouzat F; Chapon C; Ho Tsong Fang R; van der Werf S; Rosa Calatrava M; Malvy D; de Lamballerie X; Guedj J; Le Grand R
Nat Commun; 2022 Aug; 13(1):5108. PubMed ID: 36042198
[TBL] [Abstract][Full Text] [Related]
15. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
Manabe T; Kambayashi D; Akatsu H; Kudo K
BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
[TBL] [Abstract][Full Text] [Related]
16. Associations between self-reported symptoms of SARS-CoV-2 and dietary supplement use over the previous year during the first pandemic wave.
Ellis A; Bui C; Ferguson C; Azarmanesh D; Park HA
J Nutr Sci; 2023; 12():e4. PubMed ID: 36721723
[TBL] [Abstract][Full Text] [Related]
17. Disentangling post-vaccination symptoms from early COVID-19.
Canas LS; Österdahl MF; Deng J; Hu C; Selvachandran S; Polidori L; May A; Molteni E; Murray B; Chen L; Kerfoot E; Klaser K; Antonelli M; Hammers A; Spector T; Ourselin S; Steves C; Sudre CH; Modat M; Duncan EL
EClinicalMedicine; 2021 Dec; 42():101212. PubMed ID: 34873584
[TBL] [Abstract][Full Text] [Related]
18. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
19. Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
Surapat B; Kobpetchyok W; Kiertiburanakul S; Arnuntasupakul V
Int J Clin Pract; 2022; 2022():3098527. PubMed ID: 35685498
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
